Research programme: incretin stimulants - Surface LogixAlternative Names: SLx-6677
Latest Information Update: 16 Jul 2016
At a glance
- Originator Surface Logix
- Class Small molecules
- Mechanism of Action Gastric inhibitory polypeptide stimulants; Incretin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in USA
- 12 Apr 2011 Surface Logix has been acquired by Nano Terra